USA Today
SAN ANTONIO
–
Doctors were mostly hoping to prevent complications and relapses when
they gave young women a medicine to keep their bones strong during
breast cancer treatment. Seven years later, they found it did more than
that: The bone drug improved survival, as much as many chemotherapies
do.
The study found a 37 percent lower risk of death among women who received the bone drug, Zometa. In absolute terms, it meant that 4 to 5 more women out of every 100 were alive seven years later.
It's especially impressive considering
that the women took the drug, given as an infusion every six months, for
only three years... Read More
Find a Doctor/Researcher
Make an Appointment
Refer a Patient
Make a Gift
Penn Cancer Network
